The U.S. Food and Drug Administration (FDA) has accepted for review the  application for Tyvaso (inhaled treprostinil) as a potential treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The supplemental new drug application (sNDA) was submitted by United Therapeutics,…
News
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 —…
Volibris (ambrisentan) given to treat adults in China with pulmonary arterial hypertension (PAH) caused by connective tissue disease led to significant improvements in exercise capacity without signs of clinical worsening over 24 weeks, a study reported. Improvements were…
A team of researchers have used 3D cell culture technology to develop a model that replicates processes involved in pulmonary arterial hypertension (PAH), allowing them to more carefully analyze the thickening of arterial walls that occurs in patients. Their findings were detailed in the study,…
LIQ861, Liquidia Technologies’ proprietary inhaled dry powder formulation of the vasodilator treprostinil, improves exercise capacity and quality of life for people with pulmonary arterial hypertension (PAH), according to data from the Phase 3 INSPIRE trial. Treatment with LIQ861 also led…
When the COVID-19 pandemic forced the postponement of a rare disease film festival originally slated for May, its organizers set out to find a new way to bring the films to an audience. Co-founders Daniel DeFabio and Bo Bigelow, who are both fathers of children with…
The five-year survival rate is markedly reduced among adults with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD), compared with other types of CHD, real-world data from the COMPERA-CHD registry show. This worse mortality rate occurred despite the increasing number of PAH-targeted combination therapies now available for…
Aerovate Therapeutics received $72.6 million in Series A funding to advance trials testing AV-101, an experimental inhaled version of imatinib for the treatment of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder that delivers imatinib directly to a patient’s lungs.
To help people experiencing the lingering effects of coronavirus infection, the Pulmonary Wellness Foundation (PWF) has launched a free online rehabilitation and recovery program called COVID Bootcamp 101. In addition to patient education and support, the program offers breathing and other exercises conducted by a team of…
High pulmonary vascular resistance (PVR) is associated with worse mortality rates among people with pulmonary hypertension (PH), and the bottom threshold for what constitutes “elevated” PVR is lower than previously thought, a new study suggests. “The findings of this study cast the clinical profile of patients who have PH and…
Preterm babies with the lung condition bronchopulmonary dysplasia (BPD) — a risk factor for the development of pulmonary hypertension (PH) — have lower levels of the anti-aging-associated protein Klotho, a study shows. The results support the potential for Klotho as a biomarker for BPD. Moreover, early Klotho…
A case report found a patient’s pulmonary arterial hypertension (PAH) was caused by an undiagnosed case of the autoimmune disorder systemic sclerosis (SSc), highlighting the need for early and thorough diagnostic workups, researchers say. The 77-year-old woman’s PAH was also worsened by other conditions, including lung…
